Is Emergent Biosolutions Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NYSE: EBS) stock is to Strong Buy EBS stock.
Out of 1 analyst, 1 (100%) are recommending EBS as a Strong Buy, 0 (0%) are recommending EBS as a Buy, 0 (0%) are recommending EBS as a Hold, 0 (0%) are recommending EBS as a Sell, and 0 (0%) are recommending EBS as a Strong Sell.
What is EBS's forecast return on equity (ROE) for 2023-2024?
(NYSE: EBS) forecast ROE is 10.35%, which is considered weak.
What is EBS's Price Target?
According to 1 Wall Street analyst that have issued a 1 year EBS price target, the average EBS price target is $22.00, with the highest EBS stock price forecast at $22.00 and the lowest EBS stock price forecast at $22.00.
The Wall Street analyst predicted that Emergent Biosolutions's share price could reach $22.00 by May 31, 2024. The average Emergent Biosolutions stock price prediction forecasts a potential upside of 574.85% from the current EBS share price of $3.26.
What is EBS's forecast return on assets (ROA) for 2023-2024?
(NYSE: EBS) forecast ROA is 4.54%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 15.61%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.